Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Elevation Oncology
Elevation Oncology
Poseida Therapeutics, Inc.
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Blueprint Medicines Corporation
The Methodist Hospital Research Institute
VA Office of Research and Development